JP2017512996A - 代謝産物パネルに基づく血液サンプルの品質の決定のための手段および方法 - Google Patents

代謝産物パネルに基づく血液サンプルの品質の決定のための手段および方法 Download PDF

Info

Publication number
JP2017512996A
JP2017512996A JP2016558687A JP2016558687A JP2017512996A JP 2017512996 A JP2017512996 A JP 2017512996A JP 2016558687 A JP2016558687 A JP 2016558687A JP 2016558687 A JP2016558687 A JP 2016558687A JP 2017512996 A JP2017512996 A JP 2017512996A
Authority
JP
Japan
Prior art keywords
sample
marker
value
quality
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016558687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512996A5 (enExample
Inventor
カムラゲ，ビエテ
シュミッツ，オリバー
ベッサン，ビアンカ
シャッツ，フィリップ
ペーター，エーリク
Original Assignee
メタノミクス ヘルス ゲーエムベーハー
メタノミクス ヘルス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタノミクス ヘルス ゲーエムベーハー, メタノミクス ヘルス ゲーエムベーハー filed Critical メタノミクス ヘルス ゲーエムベーハー
Publication of JP2017512996A publication Critical patent/JP2017512996A/ja
Publication of JP2017512996A5 publication Critical patent/JP2017512996A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioethics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2016558687A 2014-03-26 2015-03-26 代謝産物パネルに基づく血液サンプルの品質の決定のための手段および方法 Pending JP2017512996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14161766 2014-03-26
EP14161766.2 2014-03-26
PCT/IB2015/052243 WO2015145387A1 (en) 2014-03-26 2015-03-26 Means and methods for determination of quality of blood samples based on metabolite panel

Publications (2)

Publication Number Publication Date
JP2017512996A true JP2017512996A (ja) 2017-05-25
JP2017512996A5 JP2017512996A5 (enExample) 2018-05-17

Family

ID=50433941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016558687A Pending JP2017512996A (ja) 2014-03-26 2015-03-26 代謝産物パネルに基づく血液サンプルの品質の決定のための手段および方法

Country Status (9)

Country Link
US (1) US20180217125A1 (enExample)
EP (1) EP3123174A4 (enExample)
JP (1) JP2017512996A (enExample)
KR (1) KR20160146727A (enExample)
CN (1) CN106415274A (enExample)
AU (1) AU2015237804A1 (enExample)
BR (1) BR112016021929A2 (enExample)
CA (1) CA2941979A1 (enExample)
WO (1) WO2015145387A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020524785A (ja) * 2017-06-16 2020-08-20 デーエルカー−ブルートシュペンデディーンスト・バーデン−ヴェルテンブルク−ヘッセン・ゲーゲーエムベーハーＤｒｋ−Ｂｌｕｔｓｐｅｎｄｅｄｉｅｎｓｔ Ｂａｄｅｎ−Ｗｕｒｔｔｅｍｂｅｒｇ−Ｈｅｓｓｅｎ Ｇｇｍｂｈ 単一チューブ献血者スクリーニングのための方法及び装置
WO2020225946A1 (ja) * 2019-05-09 2020-11-12 株式会社島津製作所 試料の評価方法、分析方法、劣化試料の検出方法、劣化血漿試料検出用マーカーおよび劣化血清試料検出用マーカー
WO2023022132A1 (ja) * 2021-08-17 2023-02-23 国立研究開発法人理化学研究所 成分分析装置および成分分析方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108369612A (zh) * 2015-11-04 2018-08-03 梅塔博隆股份有限公司 自动化样品质量评估
EP3628068A4 (en) * 2017-05-02 2020-12-30 Liquid Biosciences, Inc. SYSTEMS AND METHODS FOR DETERMINING THE ATTRIBUTES OF BIOLOGICAL SAMPLES
CN107818329B (zh) * 2017-08-09 2023-04-18 亿纳谱（浙江）生物科技有限公司 一种质谱数据分析方法
CN107782825A (zh) * 2017-12-01 2018-03-09 武汉迈特维尔生物科技有限公司 一种基于液相色谱检测动物体中小分子代谢物的方法
CN110609139B (zh) * 2018-06-14 2023-06-30 深圳市理邦精密仪器股份有限公司 抗原浓度过量检测方法、装置及存储介质
US20210087603A1 (en) * 2019-09-20 2021-03-25 Charite - Universitaetsmedizin Berlin Methods, kits and devices for measuring extracellular pyridine nucleotide
CN110890130B (zh) * 2019-12-03 2022-09-20 大连理工大学 基于多类型关系的生物网络模块标志物识别方法
CN111239283A (zh) * 2020-02-18 2020-06-05 深圳脉图精准技术有限公司 焦谷氨酸作为判断代谢组学血液样本质量的质检指示物的应用
CN116249904A (zh) * 2020-07-09 2023-06-09 赫尔辛基大学 用于测定来自样品的nad代谢物的量的方法以及与其相关的方法和用途
JP7600875B2 (ja) * 2021-06-01 2024-12-17 株式会社島津製作所 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033575A2 (en) * 2006-09-15 2008-03-20 Metabolon, Inc. Methods of identifying biochemical pathways
CA2728379C (en) * 2009-03-04 2016-06-14 John Wan Collection and assay device for biological fluid
PL2438445T3 (pl) * 2009-06-04 2014-12-31 Metanomics Health Gmbh Sposoby diagnozowania raków gruczołu krokowego
EP2336784B1 (en) * 2009-12-18 2017-08-16 Roche Diagnostics GmbH GDF-15 and/or Troponin T for predicting kidney failure in heart surgery patients
CN105120852A (zh) * 2013-02-14 2015-12-02 梅坦诺米克斯保健有限公司 评估生物样品质量的工具和方法
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
AU2014368412A1 (en) * 2013-12-20 2016-07-07 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTIANE ODDOZE ET AL.: "Stability study of 81 analytes in human whole blood, in serum and in plasma", CLINICAL BIOCHEMISTRY, vol. 45, no. 6, JPN6019002423, 6 January 2012 (2012-01-06), pages 464 - 469, ISSN: 0004074619 *
LINSHENG LIU ET AL.: "Differences in metabolite profile between blood plasma and serum", ANALYTICAL BIOCHEMISTRY, vol. 406, no. 2, JPN6019002424, 15 November 2010 (2010-11-15), pages 105 - 112, ISSN: 0004074620 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020524785A (ja) * 2017-06-16 2020-08-20 デーエルカー−ブルートシュペンデディーンスト・バーデン−ヴェルテンブルク−ヘッセン・ゲーゲーエムベーハーＤｒｋ−Ｂｌｕｔｓｐｅｎｄｅｄｉｅｎｓｔ Ｂａｄｅｎ−Ｗｕｒｔｔｅｍｂｅｒｇ−Ｈｅｓｓｅｎ Ｇｇｍｂｈ 単一チューブ献血者スクリーニングのための方法及び装置
WO2020225946A1 (ja) * 2019-05-09 2020-11-12 株式会社島津製作所 試料の評価方法、分析方法、劣化試料の検出方法、劣化血漿試料検出用マーカーおよび劣化血清試料検出用マーカー
JPWO2020225946A1 (ja) * 2019-05-09 2021-11-25 株式会社島津製作所 試料の評価方法、分析方法、劣化試料の検出方法、劣化血漿試料検出用マーカーおよび劣化血清試料検出用マーカー
JP7192976B2 (ja) 2019-05-09 2022-12-20 株式会社島津製作所 試料の評価方法、分析方法、劣化試料の検出方法、劣化血漿試料検出用マーカーおよび劣化血清試料検出用マーカー
JP2024020660A (ja) * 2019-05-09 2024-02-14 株式会社島津製作所 試料の評価方法、分析方法、劣化試料の検出方法、劣化血漿試料検出用マーカーおよび劣化血清試料検出用マーカー
WO2023022132A1 (ja) * 2021-08-17 2023-02-23 国立研究開発法人理化学研究所 成分分析装置および成分分析方法

Also Published As

Publication number Publication date
AU2015237804A1 (en) 2016-09-22
EP3123174A1 (en) 2017-02-01
EP3123174A4 (en) 2017-12-06
CA2941979A1 (en) 2015-10-01
CN106415274A (zh) 2017-02-15
BR112016021929A2 (pt) 2017-08-15
KR20160146727A (ko) 2016-12-21
WO2015145387A1 (en) 2015-10-01
US20180217125A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
JP2017512996A (ja) 代謝産物パネルに基づく血液サンプルの品質の決定のための手段および方法
JP6388606B2 (ja) 生物学的サンプルの質を評価するための手段及び方法
Veenstra Global and targeted quantitative proteomics for biomarker discovery
Picotti et al. Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions
CN101646942A (zh) 载脂蛋白指纹图谱技术
CN101443663A (zh) 诊断糖尿病的工具和方法
US20170276669A1 (en) Precise estimation of glomerular filtration rate from multiple biomarkers
US20200264194A1 (en) Antibody validation using ip-mass spectrometry
CN111562338A (zh) 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
Zhu Plasma/serum proteomics based on mass spectrometry
JP6389184B2 (ja) サンプルにおいて代謝産物疾患バイオマーカーのクリアランス正規化量を決定するための手段及び方法
Plubell et al. Development of highly multiplex targeted proteomics assays in biofluids using the Stellar mass spectrometer
CN115684451A (zh) 基于代谢组学的食管鳞癌淋巴结转移诊断标志物及其应用
Velstra et al. Detection of pancreatic cancer using serum protein profiling
Ogidi et al. Biomarker Discovery: Protein Phosphorylation State
Kiseleva et al. Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring
Ranasinghe et al. Fucosyl monosialoganglioside: Quantitative analysis of specific potential biomarkers of lung cancer in biological matrices using immunocapture extraction/tandem mass spectrometry
US20130266978A1 (en) Method and device for estimating molecular parameters in a sample processed by means of chromatography
EP3175379A1 (en) Means and methods for assessing a quality of a biological sample
JP2019039915A (ja) 生物学的サンプルの質を評価するための手段及び方法
Díez et al. Genomics and proteomics for biomarker validation
Di Tommaso et al. Quantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis
JP2020034556A (ja) 前立腺癌の判定方法
Hincapie et al. Multi-lectin Affinity Chromatography (M-LAC) Combined with Abundant Protein Depletion for Analysis of Human Plasma in Clinical Proteomics Applications
Kim et al. Sample preparation and profiling: mass‐spectrometry‐based profiling strategies

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303